Short answer
ACCURAY INC (ARAY) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $94M (down 7.5% year over year) with net income of −$22M.
Q3 2025 key financials · XBRL
- Revenue
- $94M
- −7.5% YoY
- Net income
- −$22M
- −448.3% YoY
- Operating margin
- -12.0%
- Gross margin
- 28.3%
- EPS (diluted)
- −$0.18
- −350.0% YoY
Source: XBRL data from the ACCURAY INC (ARAY) Q3 2025 10-Q on SEC EDGAR. USD.
ACCURAY INC Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly emphasized tariff risk, triggered by U.S. baseline 10% import tariffs and higher China tariffs
- Most material operational update, gross margins and net income pressured through fiscal 2026 by material, freight, and logistics costs
- Regulatory risk, future product modifications or new indications may require FDA 510(k) clearances or premarket approvals
- Near-term demand risk, U.S. radiotherapy budgets and customer installations expected to remain pressured through fiscal 2026
- Financial risk, $18.0 million of 3.75% Convertible Senior 2026 Notes mature June 1, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ACCURAY INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.